αVβ3 is a type of integrin that is a receptor for vitronectin. It consists of two components, integrin alpha V and integrin beta 3 (CD61), and is expressed by platelets. Furthermore, it is a receptor for phagocytosis on macrophages or dendritic cells. Integrin αVβ3 is potential drug target because abnormal expression of v3 is linked to the development and progression of various diseases. Inhibitors like etaracizumab may be used as antiangiogenics.